Trending...
- Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 105
- Avenue Dental Care North Spokane Offers Free Emergency Care to Firefighters
- City of Spokane Staff on Hand at Disaster Assistance Center
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. ("Daiichi Sankyo") relating to the parties' 2008 collaboration agreement for the use of Seagen's antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract.
"While we are disappointed with the arbitration decision, it was important for us to pursue this legal action," said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. "This does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four commercial products and a deep and diverse pipeline of promising programs. Seagen remains focused on developing innovative medicines that make a meaningful difference in the lives of cancer patients."
More on Washingtoner
About Seagen
Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Forward Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen's continued innovation and growth, as well as its pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the risk that the company's financial results may not be as expected and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by the company is contained under the caption "Risk Factors" included in Seagen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.
More on Washingtoner
Contacts
For Media
David Caouette
(310) 430-3476
dcaouette@seagen.com
For Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com
"While we are disappointed with the arbitration decision, it was important for us to pursue this legal action," said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. "This does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four commercial products and a deep and diverse pipeline of promising programs. Seagen remains focused on developing innovative medicines that make a meaningful difference in the lives of cancer patients."
More on Washingtoner
- Spokane Complex Fire Parks & Recreation update 08-12-26
- Ignazio Arces Wins Stevie® Award for Maverick of the Year at the 2026 International Business Awards
- Tickeron Highlights AI Trading Agent Performance Across Multiple Market Sectors
- Stop Bleeding Cash on Mediocre Talent. Build a Powerhouse Remote Team Instead
- Crownlight Strategies® Announces Federal Trademark Registration
About Seagen
Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Forward Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen's continued innovation and growth, as well as its pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the risk that the company's financial results may not be as expected and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by the company is contained under the caption "Risk Factors" included in Seagen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.
More on Washingtoner
- Spokane: PPE Available to Those Returning Home After New Evacuation Downgrades
- Spokane Police Respond to a Vehicle vs. Pedestrian
- New Book Calls 'Sense of Belonging' the Missing Link in Student Success
- Tacoma City Council Set to Join Pierce County's Efforts to Launch Unified Regional Approach to Reduce Homelessness
- Igbozue Connecticut USA Celebrates 2026 Summer Family Picnic
Contacts
For Media
David Caouette
(310) 430-3476
dcaouette@seagen.com
For Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com
0 Comments
Latest on Washingtoner
- Spokane Police Respond to Overnight Shooting in Garland District
- XRPPower Expands Platform Security With Enhanced Brand Protection and Official Verification Standards
- Spokane-Area VFW Posts Open Their Doors to Wildfire Evacuees
- QuickBooks Online Advanced: Features, Benefits Guide
- Cuvo Health, the #1 White Label Telehealth Platform, Surpasses 300 Exclusive Providers Serving All 50 States
- Spokane: City To Provide Extra Garbage Collection for Downgraded Evacuation Zones
- Spokane: City offers guidance on safely returning home after fires
- Qustone Brings Leadership as Infrastructure to the Commercial Space Ecosystem
- Inappropriate Jazz - It's a Musical!
- Spokane: City Testing Shows Water Quality is Safe
- RAS AP Consulting Expands Managed AP Governance™ Ecosystem, Launches Trademark Process, and Secures IFOL Speaker Invitation
- UK Financial Ltd Makes History: Chainlink CRE Circulating Supply Verification Goes Live Across Its Complete Ecosystem Of Nine Exchange-Traded Tokens
- International Rights Groups Raise Alarm Over Freedom of Religion and Expression in South Korea
- WDTA Hosts Landmark DWC Seattle AI Summit in Bellevue, Bridging AI Governance and Innovation
- City of Spokane Staff on Hand at Disaster Assistance Center
- Tacoma: Homicide Investigation – 2100 block of N 30th St
- The City's Most Elegant Open-Air Dinner Party Returns September 12, 2026
- Spokane: Incorrect Info Regarding Downgraded Evacuation Status on Popular App
- FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
- Autonomous Robotics Platform Expansion as Public Market Debut is Very Close: MBody AI Corp. (N A S D A Q: MBAI)